Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Superstring Capital Management Lp
Form 13F · Q2 2026

Superstring Capital Management Lp

CIK 1931118Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$158M
Reported book value
32
Positions
11
Quarters on record
Top 50
Positions

Superstring Capital Management Lp — holdings

Top 32 positions of 32, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1COGT Cogent Biosciences Inc343,284+52.5%$13M8.4%
2AXSM Axsome Therapeutics Inc.53,916+380.7%$13M8.3%
3GMAB Genmab A/S430,600+118.9%$12M7.5%
4CLDX Celldex Therapeutics Inc New287,583+59.7%$11M6.8%
5TRVI Trevi Therapeutics Inc524,224+108.4%$10M6.2%
6RVMD Revolution Medicines Inc51,053—$10M6.0%
7DFTX Definium Therapeutics Inc188,282−46.4%$9M5.6%
8VIR Vir Biotechnology Inc853,685+16.9%$9M5.5%
9IMVT Immunovant Inc208,368−41.7%$8M5.1%
10URGN Urogen Pharma Ltd191,313−50.6%$7M4.4%
11CLYM Climb Bio Inc521,082+161.6%$7M4.3%
12ANL Adlai Nortye Ltd552,501+33.2%$6M4.0%
13SVRA Savara Inc977,460−38.4%$6M3.8%
14MPLT Maplight Therapeutics Inc125,432−34.7%$4M2.8%
15ORIC Oric Pharmaceuticals Inc406,077+252.4%$4M2.8%
16UTHR United Therapeutics Corp Del7,172+38.3%$4M2.5%
17PCVX Vaxcyte Inc66,793−39.5%$4M2.5%
18ONC Beone Medicines Ltd12,273—$3M2.2%
19CABA Cabaletta Bio Inc1.3M+19.9%$3M2.2%
20ZLAB Zai Lab Ltd155,813−43.5%$3M1.9%
21SION Sionna Therapeutics Inc63,156−55.2%$3M1.8%
22DRUG Bright Minds Biosciences Inc30,456+128.8%$2M1.3%
23ACRS Aclaris Therapeutics Inc257,675−29.7%$1M0.9%
24HELP Cybin Inc204,424—$1M0.9%
25KNSA Kiniksa Pharmaceuticals Intl18,867—$1M0.8%
26ROIV Roivant Sciences Ltd25,623—$906,7980.6%
27TNXP Tonix Pharmaceuticals Hldg C63,648+0.2%$812,1480.5%
28TARA Protara Therapeutics Inc121,457+0.0%$463,9660.3%
29FTH Faeth Therapeutics Inc14,175—$354,3750.2%
30BOLD Boundless Bio Inc55,356—$138,3900.1%
31BMEA Biomea Fusion Inc250,000+0.0%$85,3060.1%
32VYNE THERAPEUTICS INC Vyne Therapeutics Inc61,269—$39,8680.0%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.